Voclosporin Ameliorates Proteinuria and Directly Protects Podocytes in a Model of Noninflammatory Glomerular Disease (KIDNEY WEEK 2024) - Sep 23, 2024 - Abstract #SA-PO709; Pres time: Oct 26, 2024; 10:00 AM - 12:00 PM; Location: Exhibit Hall, Convention Center; "We investigated whether VCS could reduce proteinuria in a non-inflammatory animal model of NS. Rats received 50 mg/kg puromycin aminonucleoside (PAN) or saline via tail vein injection and were gavaged twice daily with vehicle (VEH, vitamin E-TPGS, MCT oil, Tween 40, and 95% ethanol 4:2:2:1, by weight), VCS (4 mg/kg/dose), or cyclosporine (CsA, 10mg/kg/dose) as clinically relevant doses. Compared to CsA, a clinically relevant dose of VCS more effectively ameliorated PAN-induced proteinuria, hypercoagulopathy, NS-associated dyslipidemia, and tubular injury in rats, as well as cell viability and actin cytoskeleton of cultured podocytes."
Dyslipidemia • Glomerulonephritis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Renal Disease
|
|
Yu Kamigaki, MD; Julie Dougherty, PhD; Amanda P. Waller, PhD; Linda M. Rehaume, PhD; Laura Biederman, MD; Bryce A. Kerlin, MD; William E. Smoyer, MD
|